Previous 10 | Next 10 |
Eton Pharmaceuticals (ETON) -10%.Genetic Technologies (GENE) -8% GENE COVID-19 risk test launched in USAZIM Integrated Shipping Services (ZIM) -7% after launches secondary equity offeringeMagin (EMAN) -6%.AeroCentury (ACY) -6%.Mind Medicine (MNMD) -5%. For further details see...
Gainers: SemiLEDs (LEDS) +49%.Vertex Energy (VTNR) +45%.Organovo (ONVO) +28%.eMagin (EMAN) +24%.Mannatech (MTEX) +21%.Welbilt (WBT) +21%.Yext (YEXT) +19%.MoSys (MOSY) +16%.Embotelladora Andina (AKO-B) +13%.Iterum Therapeutics (ITRM) +17%.Losers: 1847 Goedeker (GOED) -70%.M...
Gainers: Organovo (ONVO) +24%, Iterum Therapeutics (ITRM) +16%, Adagene (ADAG) +14%, Freeline Therapeutics (FRLN) +12%, 180 Life Sciences (ATNF) +12%.Losers: Provention Bio (PRVB) -22%, Eton Pharmaceuticals (ETON) -13%, Lannett (LCI) -12%...
Eton Pharmaceuticals (ETON) announces that the U.S. FDA has declined to approve the company's dehydrated alcohol injection for the treatment of methanol poisoning.The complete response letter from the health regulator indicated that the FDA has completed its review of the application and has ...
DEER PARK, Ill., May 28, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), today announced that the company has received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration (FDA) in response to the submission of its New Drug Application (NDA) for d...
HROWL yields 8.3% and has outstanding call protection. HROW has more cash and marketable securities than debt. HROW reported blowout Q1 earnings and the stock has nearly doubled over the last year. The $55 million of HROWL debt is dwarfed by the $250 million equity market capi...
Eton Pharmaceuticals, Inc. (ETON) Q1 2021 Earnings Conference Call May 13, 2021, 04:30 PM ET Company Participants David Krempa - Vice President, Business Development Sean Brynjelsen - Chief Executive Officer Wilson Troutman - Chief Financial Officer Paul Stickler - Senior Vice President, Sale...
Eton Pharmaceuticals (ETON): Q1 GAAP EPS of $0.19 in-line.Revenue of $11.9M (+11800.0% Y/Y) misses by $0.15M.Eton reported cash and cash equivalents of $25.1 million as of March 31, 2021.Shares +9.18%.Press Release For further details see: Eton Pharmaceuticals EPS in-line, misses on rev...
First quarter 2021 revenue of $11.9 million First quarter 2021 operating earnings of $5.4 million; EPS of $0.19 Eton now has three commercial, revenue-generating products DEER PARK, Ill., May 13, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovat...
DEER PARK, Ill., May 04, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2021 financial and operating results on ...
News, Short Squeeze, Breakout and More Instantly...
Eton Pharmaceutcials Inc. Company Name:
ETON Stock Symbol:
NASDAQ Market:
Eton Pharmaceutcials Inc. Website:
- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent protection through 2043 - DEER PARK, Ill., July 15, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innov...
• Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13 th straight quarter of sequential product sales growth • Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...